A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
NCT07174583
This study is recruiting at 13 US sites in 10 states, according to its ClinicalTrials.gov record last updated .
Summary
This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Small-cell Lung Cancer
- Neuroendocrine Carcinomas
- Solid Tumor Show to Express DLL3
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- IDEAYA Biosciences
- Last updated on ClinicalTrials.gov
- July 9, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- Sarah Cannon Research Institute at HealthONE · Denver, CO
Florida · 1
- Sarah Cannon Research Institute at Florida Cancer Specialists · Orlando, FL
Indiana · 1
- Fort Wayne Medical Oncology and Hematology, Inc. - Fort Wayne North Office · Fort Wayne, IN
Michigan · 2
- START Midwest · Grand Rapids, MI
- The Cancer and Hematology Centers · Grand Rapids, MI
New York · 1
- Columbia University Medical Center - Herbert Irving Pavilion · New York, NY
Pennsylvania · 1
- Sidney Kimmel Cancer Center at Thomas Jefferson University · Philadelphia, PA
Tennessee · 1
- Sarah Cannon Research Institute - Oncology Partners · Nashville, TN
Texas · 3
- Oncology Consultants, PA- Houston · Houston, TX
- The University of Texas MD Anderson Cancer Center · Houston, TX
- Next Oncology Dallas · Irving, TX
Virginia · 1
- NEXT Oncology Virginia · Fairfax, VA
Washington · 1
- Swedish Cancer Institute · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.